The study used the PD325901, a MEK inhibitor that blocks ERK phosphorylation, as the MAPK/ERK pathway inhibitor in combination with BMI1 inhibition to evaluate synergistic effects on medulloblastoma cells [129]. This evidence concerns the gene BMI1 and medulloblastoma.